INDP (Indaptus Therapeutics Inc.) stock: $3.32, $509.9M market cap, $11.6M cash, $498.3M EV, $448.6M fully diluted market cap. Next expected readout: Jun-27. Lead program: Decoy20 (Solid Tumor, Adult), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
We are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Phase 1 dose-escalation/expansion trial (mono and combination with a tumor antigen) discontinued: no further enrollment, no participants remaining, and no active clinical development programs as of the 10-Q. Company is evaluating strategic alternatives for the Decoy20 program and broader business.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.